Ranjan Pathak is an Oncology physician affiliated with California State University, Chico. OpenAlex indexes 165 publications with 2,406 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
265 Cohasset Rd
Chico, CA 959262273
Telephone
530-332-4700Provider last certified this registry record 30 Dec 2022.
Clinical trials
- A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention
Sponsor: University of California, Davis
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20232 payments
- PFIZER INC.Program year20223 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
33.8%Kinase inhibitor9.3%Verzenio28%Calquence27%Inlyta17%Imatinib Mesylate15%Tasigna14%Part D<11 patientsCytochrome P450 17A1 Inhibitor6.4%Abiraterone Acetate100%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
25.3%Corticosteroid9.4%Prednisone100%Part D≥31 patientsSerotonin-3 Receptor Antagonist8.1%Ondansetron Hcl86%Ondansetron Odt14%Part D<11 patients+ 3 more classes in this area
Nervous system
21.5%Opioid Agonist7.6%Morphine Sulfate Er32%Oxycodone Hcl30%Oxycodone-Acetaminophen24%Morphine Sulfate14%Part D<11 patientsPhenothiazine7%Prochlorperazine Maleate100%Part D≥37 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cancer Survivors, Oncology, and Primary Care Perspectives on Survivorship Care: An Integrative Review
Journal of Primary Care & Community Health
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”